论文部分内容阅读
目的 探讨利用放射性核素示踪技术研究半乳糖抗小鼠CD3 单克隆抗体 (Gal Ant CD3McAb)作为原发性肝癌 (PLC)术后免疫治疗载体的可行性。方法 以半乳糖 (Gal)为原料 ,制得 2 亚氨基 2 甲氧乙基 1 硫代 β D 半乳糖苷 (IME) ,与抗小鼠CD3 单克隆抗体 (Ant CD3 McAb)共价偶联制得Gal Ant CD3 McAb ,再用1 3 1 I或1 2 5 I标记Gal Ant CD3 McAb和Ant CD3 McAb ,通过小鼠体内分布实验和家兔显像实验 ,对比研究两者肝化差异 ;将Gal Ant CD3 McAb与肿瘤浸润淋巴细胞 (TIL)联接制得Gal Ant CD3 McAb TIL ,研究其体外趋肝性和杀伤自体肿瘤细胞作用。结果 Gal Ant CD3 McAb具有明显的趋肝性 ,每克肝组织最大摄取率为注入量的 (5 9 0± 2 1) % ,是Ant CD3 McAb的 2倍以上 ;Gal Ant CD3 McAb TIL在体外有良好的趋肝性 ,且杀伤自体肿瘤细胞的作用极强。结论 Gal Ant CD3McAb有可能作为PLC术后免疫治疗的载体
Objective To investigate the feasibility of using Gal Ant CD3 McAb as a carrier for postoperative immunotherapy of primary hepatocellular carcinoma (PLC) using radionuclide tracer technique. Methods 2-amino-2-methoxyethyl thiogalactopyranoside (IME) was synthesized from galactose (Gal) and covalently coupled with anti-mouse CD3 monoclonal antibody (Ant CD3 McAb) Gal Ant CD3 McAb was obtained, and Gal Ant CD3 McAb and Ant CD3 McAb were labeled with 131I or 125I. The in vivo distribution in mice and the imaging in rabbits were used to compare the differences between the two groups. Gal Ant-CD3 McAb and tumor-infiltrating lymphocytes (TIL) were used to produce Gal Ant CD3 McAb TIL. The antitumor activity of Gal Ant CD3 was studied in vitro. Results The Gal Ant CD3 McAb had a significant hepatic gain. The maximum uptake rate per gram of liver tissue was (59 0 ± 2 1)%, which was more than twice that of Ant CD3 McAb. Gal Ant CD3 McAb TIL was found in vitro Good hepatotrophic, and killing autologous tumor cells is extremely strong. Conclusion Gal Ant CD3McAb may serve as a carrier for post-PLC immunotherapy